Takeda axes clinical-stage program in $1B+ Turnstone Biologics collaboration
Takeda has ended its work with Turnstone Biologics on a solid tumor asset that was in a Phase I/IIa study, upending a 2019 deal that had $900 million in biobucks on the line.
The Japanese Big Pharma disclosed it was dropping TAK-605 and returning the armored oncolytic virus back to the New York biotech for “strategic reasons,” according to a quarterly update Thursday morning. Turnstone regains the global rights to the asset, also named RIVAL-01.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.